Halozyme Therapeutics (HALO) SEC Filings & 10K Form

$38.57
+0.11 (+0.29%)
(As of 04/26/2024 08:52 PM ET)

Recent Halozyme Therapeutics SEC Filings

DateFilerForm TypeView
04/26/2024
3:22 PM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2024
6:22 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2024
6:38 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:46 PM
Halozyme Therapeutics (Filer)
Form ARS
03/15/2024
3:18 PM
Halozyme Therapeutics (Filer)
Form DEFA14A
03/13/2024
4:22 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2024
3:14 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
3:13 PM
Halozyme Therapeutics (Filer)
Form PRE 14A
02/28/2024
5:49 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/28/2024
3:07 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/20/2024
5:53 PM
Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:55 PM
Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:59 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:49 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:39 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:41 PM
Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:47 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2024
5:19 AM
Artisan Partners Limited Partnership (Filed by)
Halozyme Therapeutics (Subject)
Form SC 13G/A
02/01/2024
2:51 PM
Halozyme Therapeutics (Subject)
Invesco Ltd. (Filed by)
Form SC 13G/A
01/17/2024
3:56 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2024
7:10 AM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/16/2024
3:26 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/13/2023
6:48 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/13/2023
3:40 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/12/2023
3:21 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2023
3:19 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/06/2023
3:04 PM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2023
3:07 PM
Halozyme Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/17/2023
6:28 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2023
3:30 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/07/2023
6:14 AM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/31/2023
4:35 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2023
3:23 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/29/2023
4:35 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/23/2023
4:08 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2023
3:20 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/17/2023
5:12 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/17/2023
4:29 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/16/2023
4:11 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2023
4:02 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2023
2:31 PM
Daly James M (Reporting)
Halozyme Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
It’s now possible to know the win rate of every trade… BEFORE you take it! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here <<
08/11/2023
5:44 PM
Daly James M (Reporting)
Halozyme Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/19/2023
3:10 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2023
3:28 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/22/2023
5:20 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
3:36 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2023
1:15 PM
Halozyme Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
05/09/2023
5:09 PM
BIZZARI JEAN-PIERRE (Reporting)
Halozyme Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2023
5:12 PM
Connaughton Bernadette (Reporting)
Halozyme Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2023
5:14 PM
Daly James M (Reporting)
Halozyme Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2023
5:16 PM
Duncan Barbara Gayle (Reporting)
Halozyme Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2023
5:19 PM
Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2023
5:21 PM
Halozyme Therapeutics (Issuer)
MATSUI CONNIE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2023
5:24 PM
Halozyme Therapeutics (Issuer)
Miyashita Akiko Moni (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2023
5:27 PM
Halozyme Therapeutics (Issuer)
Posard Matthew L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:HALO) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners